EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.

PIK-75 at half-IC 50 concentration (chosen to limit cell death) showed a strong trend to reduce the invasive capacity of UWG02CTC compared to no drug control ( Figure 4 E).

also in 5,725 other papers

Summary In summary, our findings strongly indicate for the first time that the combination treatment with either PIK-75 or alpelisib with gefitinib is very effective against PIK3CA -mutated HER2-negative mGAC, a highly significant result given the paucity of targeted treatment options in HER2-negative mGAC.

also in 132,142 other papers